Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

RNAC 11.05.2024

Full Press ReleaseSEC FilingsOur RNAC Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
  • 01.07.2025 - Julian Harrison
  • 01.07.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants

Recent Filings

  • 01.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EFFECT Notice of Effectiveness

FREDERICK, Md.,Nov. 05, 2024(GLOBE NEWSWIRE) --Cartesian Therapeutics, Inc.(NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66thAmerican Society of Hematology(ASH) Annual Meeting and Exposition, being heldDecember 7-10, 2024inSan Diego. A copy of the abstract is available on the ASH website atwww.hematology.org.

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Details of the poster presentation are as follows:

  • Publication Number:2080
  • Title:Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases
  • Presenter:Miloš Miljković, M.D.,M.Sc., Chief Medical Officer,Cartesian Therapeutics
  • SessionName:704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
  • Session Date/Time:Saturday, December 7, 2024,5:30-7:30 p.m. PT
  • Location:San Diego Convention Center, Halls G-H

In addition, the poster was selected for inclusion in the ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights. The Poster Walk, which aims to highlight cutting-edge emerging science featured at the meeting, will take place onMonday, December 9, 2024, at7:30 a.m. PTin theBlood Journal Studiolocated in the Poster Hall.

About Descartes-08Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell maturation antigen (BCMA) in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythematosus. In contrast to conventional DNA-based CAR T-cell therapies, mRNA CAR-T administration is designed so that it does not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by theU.S. Food and Drug Administrationfor the treatment of MG.

AboutCartesian TherapeuticsCartesian Therapeuticsis a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next generation, autologous anti-BCMA mRNA CAR-T. For more information, please visitwww.cartesiantherapeutics.comor follow the Company onLinkedInorX, formerly known as Twitter.

Investor ContactMelissa ForstArgot Partnerscartesian@argotpartners.com

Media ContactDavid RosenArgot Partnersdavid.rosen@argotpartners.com

Primary Logo

Source: Cartesian Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com